Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Sees Significant Decline in Short Interest

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) was the target of a large decrease in short interest in March. As of March 31st, there was short interest totaling 376,288 shares, a decrease of 16.8% from the March 15th total of 452,420 shares. Currently, 8.0% of the company’s stock are sold short. Based on an average daily volume of 37,885 shares, the days-to-cover ratio is currently 9.9 days.

Institutional Investors Weigh In On Coeptis Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Marshall Wace LLP acquired a new stake in Coeptis Therapeutics during the fourth quarter worth about $259,000. State Street Corp raised its stake in Coeptis Therapeutics by 35.0% during the fourth quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after acquiring an additional 6,962 shares during the period. Geode Capital Management LLC raised its stake in Coeptis Therapeutics by 12.6% during the fourth quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after acquiring an additional 4,721 shares during the period. Steward Partners Investment Advisory LLC raised its stake in Coeptis Therapeutics by 100.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock worth $71,000 after acquiring an additional 2,500 shares during the period. Finally, Yorkville Advisors Global LP acquired a new stake in Coeptis Therapeutics during the third quarter worth about $140,000. Institutional investors and hedge funds own 13.88% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Coeptis Therapeutics in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

Coeptis Therapeutics Stock Up 7.1%

Shares of Coeptis Therapeutics stock traded up $0.92 during trading on Thursday, reaching $13.91. The company had a trading volume of 47,183 shares, compared to its average volume of 50,365. The company has a market cap of $86.56 million, a price-to-earnings ratio of -4.67 and a beta of -0.44. The firm’s fifty day moving average is $11.78 and its 200-day moving average is $13.98. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.16 and a current ratio of 4.16. Coeptis Therapeutics has a fifty-two week low of $6.26 and a fifty-two week high of $21.41.

Coeptis Therapeutics (NASDAQ:COEP) last issued its earnings results on Thursday, March 19th. The company reported ($0.12) earnings per share (EPS) for the quarter. The company had revenue of $0.86 million during the quarter. Coeptis Therapeutics had a negative net margin of 803.96% and a negative return on equity of 110.89%.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.